Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB
Mandate

Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB

April 06, 2022 Employment and Benefits M&A Intellectual Property IT, Telecommunications and Outsourcing Commercial Agreements

Blika provides a modular, best-of-breed SaaS system which allows companies to monitor legal structures ensuring proper governance and compliance. The platform helps enterprises to comply with tax, legal and transfer pricing regulations such as DAC6 and IFRIC 23.

Blika is headquartered in Stockholm with additional offices in Kalmar and Oskarshamn and has a large client base comprising European and global multinational businesses including Fortune 500 companies.

Vinge’s team consisted of Filip Öhrner, Manne Bergström, Egil Svensson (M&A), Veronika Garemark, Elin Broman (Employment), Rebecka Målquist (IP), Lisa Hörnqvst, Karolina Fuhrman (Commercial Agreements, IT & GDPR) and Jessica Henning (VDR Assistant).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025